Model costs
| Cost . | Baseline, US$ . | Range, US$ . | Study or data source . |
|---|---|---|---|
| Venetoclax 400 mg daily, per mo | 11 741.61 | — | 25 |
| Gilteritinib 120 mg daily, per mo | 23 044.80 | — | 25 |
| Ivosidenib 500 mg daily, per mo | 26 831.07 | — | 25 |
| Enasidenib 100 mg daily, per mo | 26 440.94 | — | 25 |
| Voriconazole 200 mg twice daily, per mo | 498.61 | — | 25 |
| Azacitidine 75 mg/m2, per dose | 160.20 | — | J9025 |
| Filgrastim (Granix) 5 μg/kg, per dose | 225.60 | — | J1447 |
| Chemotherapy subcutaneous injection | 80.12 | 69.07-105.81 | CPT 96401 |
| Outpatient visits, per mo | 682.57 | 341.29-1023.86 | 26 |
| Transfusion support, per mo | 3882.14 | 1941.07-5823.20 | 26 |
| Best supportive care, per mo | 5094.56 | 2547.28-7641.84 | 27 |
| Hospitalization for venetoclax ramp-up | 8246.81 | — | DRG 836 |
| End-of-life care | 188 677.66 | 94 338.83-283 016.50 | 28 |
| Cost . | Baseline, US$ . | Range, US$ . | Study or data source . |
|---|---|---|---|
| Venetoclax 400 mg daily, per mo | 11 741.61 | — | 25 |
| Gilteritinib 120 mg daily, per mo | 23 044.80 | — | 25 |
| Ivosidenib 500 mg daily, per mo | 26 831.07 | — | 25 |
| Enasidenib 100 mg daily, per mo | 26 440.94 | — | 25 |
| Voriconazole 200 mg twice daily, per mo | 498.61 | — | 25 |
| Azacitidine 75 mg/m2, per dose | 160.20 | — | J9025 |
| Filgrastim (Granix) 5 μg/kg, per dose | 225.60 | — | J1447 |
| Chemotherapy subcutaneous injection | 80.12 | 69.07-105.81 | CPT 96401 |
| Outpatient visits, per mo | 682.57 | 341.29-1023.86 | 26 |
| Transfusion support, per mo | 3882.14 | 1941.07-5823.20 | 26 |
| Best supportive care, per mo | 5094.56 | 2547.28-7641.84 | 27 |
| Hospitalization for venetoclax ramp-up | 8246.81 | — | DRG 836 |
| End-of-life care | 188 677.66 | 94 338.83-283 016.50 | 28 |